Market Newsdesk

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026.

The Company will host a conference call and webcast at 8:30 AM ET that morning to review financial results and provide a corporate update focused on the clinical advancement of agenT-797, MiNK’s off-the-shelf allogeneic iNKT cell therapy, in acute lung injury.

The update will include new clinical data on the progress of agenT-797 in patients with pulmonary injury, as well as details regarding the launch of MiNK’s named-patient program.

Webcast & Replay Information

A live webcast and replay of the conference call will be accessible from the Events & Presentations page of the Company’s website following the event.

Live event link:
https://edge.media-server.com/mmc/p/zkuebhpc

Webcast Replay: https://investor.minktherapeutics.com/events-and-presentations

About MiNK Therapeutics

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the development of allogeneic invariant natural killer T (iNKT) cell therapies and precision immune modulators designed to restore immune balance and drive durable cytotoxic responses. MiNK’s proprietary iNKT platform bridges innate and adaptive immunity to address cancer, autoimmune disease, and immune collapse.

Its lead candidate, agenT-797, is an off-the-shelf, cryopreserved iNKT cell therapy currently in clinical trials for solid tumors, graft-versus-host disease (GvHD), and critical pulmonary immune failure. MiNK’s pipeline also includes TCR-based and neoantigen-targeted iNKT programs that enable tissue-specific immune activation. With a scalable manufacturing process and broad therapeutic potential, MiNK is advancing a new class of immune reconstitution therapies designed to deliver durable, accessible, and globally deployable treatments.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws, including statements regarding the potential, safety, clinical benefit, and development plans for agenT-797 and other iNKT-based therapies. These statements involve risks and uncertainties, including those described under “Risk Factors” in MiNK’s most recent SEC filings. MiNK undertakes no obligation to update these statements except as required by law.

Contacts

Investor Contact: 917-362-1370 | [email protected]
Media Contact: 781-674-4428 | [email protected]

Source: MiNK Therapeutics

Initial agreement contemplates the purchase of up to 128 NVIDIA HGX B300 AI systems with an estimated aggregate hardware value of approximately $77 million based on current market pricing, subject to future purchase orders and customary conditions

HOUSTON, Aug. 06, 2026 (GLOBE NEWSWIRE) — via IBN – AZIO AI Holdings, Inc. (NASDAQ: AZIO) (“AZIO AI” or the “Company”), today announced that it has entered into an agreement with Power Champion Investment Limited (“Power Champion”) covering the purchase of up to 128 NVIDIA HGX B300 GPU systems for deployment at U.S.-based AI infrastructure facilities.

Based on current market pricing of $600,000 per NVIDIA HGX B300 system (which is an approximate midpoint of the range of current market prices from $472,000 to $720,000 per unit, depending on customer customization), the Company estimates the agreement will represent an approximate aggregate hardware value of $77 million, assuming all contemplated systems are purchased by Power Champion and subject to the agreement’s terms and customary conditions. Actual revenues under this agreement may vary based on market prices, delivered volume and timing.

The agreement aligns with the initial phase of the commercial relationship between AZIO AI and Power Champion’s initial hosting agreement, announced on July 9, 2026 and supports the planned deployment of next-generation AI compute infrastructure.

“This agreement reflects continued momentum in our commercial relationship with Power Champion and demonstrates growing demand for enterprise AI infrastructure,” said Chris Young, Chief Executive Officer of AZIO AI.

About AZIO AI Holdings, Inc.

AZIO AI Holdings, Inc. is a technology infrastructure company focused on developing, owning, and operating artificial intelligence data centers, enterprise GPU compute infrastructure, digital power solutions, and digital asset mining operations.

The Company operates an integrated AI infrastructure business encompassing AI data center development, the sale and distribution of enterprise GPU systems and server infrastructure, high-performance computing solutions, power hosting, and strategic technology investments, serving enterprise and institutional customers across domestic and international markets.

Through this diversified AI infrastructure strategy, the Company is positioned to capitalize on the rapidly expanding global demand for AI infrastructure, compute capacity, digital power, and next-generation AI technologies.

For more information, visit: www.azioai.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by words such as “may,” “will,” “could,” “expect,” “anticipate,” “believe,” “estimate,” “project,” “intend,” “continue,” “potential,” “ongoing,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements include statements regarding the expected sales and revenue under the Power Champion agreement, including Power Champion’s delivery of purchase orders thereunder; the Company’s ability to capitalize on accelerating demand for AI infrastructure; the Company’s plans to continue expanding its deployment of NVIDIA HGX B300 infrastructure; the ability to advance and execute against the Company’s commercial infrastructure pipeline; and the Company’s broader business strategy and long-term growth objectives.

These statements are based on current expectations and assumptions that involve risks and uncertainties that could cause actual results to differ materially. Most of these factors are outside the Company’s control and are difficult to predict. Factors that may affect actual results include, but are not limited to, the Company’s limited operating history within AI infrastructure and compute operations, project scope, engineering challenges, supply chain constraints, installation timelines, energy availability, finalization of site usage rights, regulatory considerations, equipment performance, ability to raise capital required for expansion activities, changes in digital asset markets, evolving compute demand, market conditions, and additional risks and uncertainties described in the Company’s most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q filed with the SEC, which are available at www.sec.gov. The Company undertakes no obligation to update forward-looking statements except as required by law.

Media Contact:

AZIO AI Holdings
Merrick Alpert, Chief Communications Officer
Telephone: (870) 970-3355
Email: [email protected]

InvestorWire Service Contact:

IBN.Ai
Austin, Texas
www.IBN.ai
512.354.7000 Office
[email protected]

NEW YORK, Aug. 06, 2026 (GLOBE NEWSWIRE) — E.F. Hutton & Co. (“E.F. Hutton”), a leading investment banking and financial advisory firm, today announced that it acted as exclusive financial advisor in connection with a $5.5 million financing for Lōkahi Therapeutics™, a subsidiary of Glucotrack, Inc. (Nasdaq: GCTK).

The financing was led by participating institutional investors and consisted of a $2.0 million equity financing, priced at $0.75 per unit, together with a $3.5 million follow-on investment in the form of convertible debt.

Joseph T. Rallo, Chief Executive Officer of E.F. Hutton, commented, “We are pleased to have advised Lōkahi Therapeutics and Glucotrack on this important financing. The transaction reflects the continued confidence of institutional investors in the Company’s long-term strategy and provides additional capital to support the advancement of its innovative therapeutic platform. We appreciate the opportunity to work alongside the management team on this successful financing and look forward to supporting the Company’s continued growth.”

About E.F. Hutton & Co.

E.F. Hutton & Co. is a full-service investment bank and broker-dealer headquartered in New York City, serving corporations, financial sponsors, and institutional investors across the U.S., Asia, Europe, the UAE, and Latin America. We provide a comprehensive range of investment banking and capital markets services across our specialized divisions, delivering integrated solutions at every stage of the capital lifecycle. For more information, please visit www.efhutton.com.

Contact Information

E.F. Hutton & Co.
[email protected]
www.efhutton.com   
(212) 970-3700

• PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-term
• BLA completion for HR BCG-unresponsive NMIBC expected fourth quarter 2026
• Phase 3 BOND-003 Cohort C Study Results published in The Lancet Oncology, further validating the strength of the clinical evidence supporting cretostimogene
• Well-positioned to deliver on key milestones with approximately $1.0 billion cash, cash equivalents and marketable securities sufficient to fund operations through 2029

DALLAS, Texas, Aug. 06, 2026 (GLOBE NEWSWIRE) — CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the second quarter ended June 30, 2026, and provided business updates.

“This quarter we have made significant progress across our clinical, regulatory, manufacturing and commercial-readiness initiatives, positioning the Company for long-term success.  PIVOT-006 has accrued the vast majority of the target events, and we look forward to sharing topline results soon. We are confident in the potential of cretostimogene and are committed to delivering what we believe will be a backbone therapy for patients,” stated Arthur Kuan, Chairman & Chief Executive Officer at CG Oncology.

Corporate Highlights

• In July, BOND-003 Cohort C Study Results were published in The Lancet Oncology validating the strength of the clinical evidence supporting cretostimogene
  • Title: Intravesical cretostimogene grenadenorepvec oncolytic immunotherapy in high-risk, BCG-unresponsive, non-muscle invasive bladder cancer with carcinoma in situ (BOND-003 Cohort C): a single-arm, phase 3 trial
• In July, the Superior Court of the State of Delaware denied ANI’s post-trial motion for a new trial and judgment as a matter of law, upholding the jury’s verdict in favor of CG Oncology that the invalidated royalty provision was properly severed and that the remainder of the agreement with ANI remains in force, while rejecting ANI’s challenges to the verdict and related claims
• In May, CORE-008 Cohort CX data were presented at the Society of Urologic Oncology (SUO) session at the American Urological Association (AUA) 2026 Annual Meeting

Anticipated 2026 Milestones

• PIVOT-006 (intermediate-risk NMIBC): Phase 3 topline data
• Completion of BLA submission in initial indication of HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease in 4Q’26
• BOND-003 Cohort C (HR BCG-unresponsive NMIBC with CIS with or without Ta/T1 disease), BOND-003 Cohort P (HR BCG-unresponsive NMIBC in Ta/T1 disease without CIS), CORE-008 Cohort CX (HR BCG-exposed and BCG-unresponsive NMIBC) and CORE-008 Cohort A (HR BCG-naïve NMIBC with CIS +/- Ta/T1), durability data

Second Quarter Financial Highlights

• Cash Position: Cash, cash equivalents and marketable securities as of June 30, 2026 were $1.0 billion, compared with $1.1 billion as of March 31, 2026.  The Company anticipates its existing cash, cash equivalents and marketable securities as of this date will be sufficient to fund operations through 2029.
• Research and Development (R&D) Expenses: R&D expenses were $54.7 million for the second quarter of 2026, as compared to $31.3 million for the prior year period. The increase was primarily due to an increase in clinical trial expenses, including CMC costs, and an increase in compensation costs due to increased headcount.
• General and Administrative (G&A) Expenses: G&A expenses were $29.0 million for the second quarter of 2026, as compared to $17.4 million for the prior year period. The increase was primarily attributed to an increase in personnel-related expenses, including compensation costs from increased headcount.
• Net Loss: Net loss was $79.1 million, or $(0.90) per share, for the second quarter of 2026, as compared to a net loss of $41.4 million, or $(0.54) per share, for the prior year period.

About Cretostimogene Grenadenorepvec

Cretostimogene is an investigational, intravesically delivered oncolytic immunotherapy that has been studied in a clinical development program, which includes more than 600 patients with Non-Muscle Invasive Bladder Cancer (NMIBC). This program includes two Phase 3 clinical trials: BOND-003 for high-risk BCG-unresponsive NMIBC and PIVOT-006 for intermediate-risk NMIBC. CG Oncology also has a multi-cohort Phase 2 trial, CORE-008, evaluating the safety and efficacy of cretostimogene in high-risk NMIBC. Additionally, we have initiated an Expanded Access Program for cretostimogene in North America for patients who are unresponsive to BCG and meet certain program eligibility requirements. Cretostimogene is an investigational candidate, and its safety and efficacy have not been established by the FDA or any other health authority.

About CG Oncology

CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.

Forward-Looking Statements

CG Oncology cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. The forward-looking statements are based on our current beliefs and expectations and include, but are not limited to, statements regarding our anticipated cash runway, future results of operations and financial position; the anticipated timing and conduct of our ongoing and planned clinical trials and preclinical studies for cretostimogene, including anticipated next milestones in our development pipeline; the timing and likelihood of regulatory filings and approvals for cretostimogene; the potential therapeutic benefits of cretostimogene for high-risk and intermediate-risk NMIBC patients; and that cretostimogene has a best-in-disease product profile. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in our business, including, without limitation: interim results of a clinical trial are not necessarily indicative of final results and one or more of the clinical outcomes may materially change as patient enrollment continues, following more comprehensive reviews of the data, and as more patient data becomes available; potential delays in the commencement, enrollment and completion of clinical trials, including the BOND-003 and PIVOT-006 trials; we may use our capital resources sooner than expected and they may be insufficient to allow us to achieve our anticipated milestones; our dependence on third parties in connection with manufacturing, shipping and clinical and preclinical testing; results from earlier clinical trials and preclinical studies not necessarily being predictive of future results; unexpected adverse side effects or inadequate efficacy of cretostimogene that may limit its development, regulatory approval, and/or commercialization; and other risks described in our filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in our annual report on Form 10-K and other filings that we make with the SEC from time to time (which are available at http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Contacts:

Media
Sarah Connors
Vice President, Communications and Patient Advocacy, CG Oncology
[email protected]

Investor Relations
Megan Knight
Vice President, Investor Relations, CG Oncology
[email protected]

JACKSONVILLE, Fla., Aug. 06, 2026 (GLOBE NEWSWIRE) — Regency Centers Corporation (“Regency Centers,” “Regency” or the “Company”) (NASDAQ: REG) announced today that the Company’s Board of Directors (the “Board”) declared quarterly cash dividends on Regency’s common stock, Series A preferred stock, and Series B preferred stock, respectively. 

• On August 5, 2026, the Board declared a quarterly cash dividend on the Company’s common stock of $0.755 per share. The dividend is payable on October 2, 2026, to shareholders of record as of September 11, 2026. 
• On August 5, 2026, the Board declared a quarterly cash dividend on the Company’s Series A preferred stock of $0.390625 per share. The dividend is payable on October 30, 2026, to shareholders of record as of October 15, 2026. 
• On August 5, 2026, the Board declared a quarterly cash dividend on the Company’s Series B preferred stock of $0.367200 per share. The dividend is payable on October 30, 2026, to shareholders of record as of October 15, 2026. 

About Regency Centers Corporation (NASDAQ: REG) 

Regency Centers is a preeminent national owner, operator, and developer of shopping centers located in suburban trade areas with compelling demographics. Our portfolio includes thriving properties merchandised with highly productive grocers, restaurants, service providers, and best-in-class retailers that connect to their neighborhoods, communities, and customers. Operating as a fully integrated real estate company, Regency Centers is a qualified real estate investment trust (REIT) that is self-administered, self-managed, and an S&P 500 Index member. For more information, please visit RegencyCenters.com 

Kathryn McKie
904 598 7348
[email protected]

This press release was published by a CLEAR® Verified individual.

SEATTLE, Aug. 06, 2026 (GLOBE NEWSWIRE) — Banzai International, Inc. (NASDAQ: BNZI) (“Banzai” or the “Company”) today announced that its Board of Directors has approved, and will submit for shareholder approval, a proposal to change the Company’s corporate name to “Parabolic Technologies, Inc.” (“Parabolic”). The Company believes that the future of enterprise software will be agentic applications that are net-beneficiaries of AI transformation, and it plans to focus on building, acquiring, and investing in those and related businesses. The Company will operate its current business units and continue to invest in the development of their AI features.

Pending shareholder approval, the Company will operate under the d/b/a “Parabolic” and will continue trading on the Nasdaq Capital Market under the new ticker symbol PARA. The Company plans to seek shareholder approval to change its legal name to Parabolic Technologies, Inc. at a future shareholders’ meeting. The Company has launched its new website at www.parabolic.io.

Concurrently with the proposed rebranding, the Company also announced a new business unit structure designed to align leadership and go-to-market execution with its evolved vision. The Company’s operations will be organized into three business units: ConnectAndSell, the Company’s AI sales acceleration platform, led by President and General Manager Jonti McLaren; Banzai, which will operate the Company’s Demio and OpenReel products, led by President and General Manager Matt McCurdy; and CreateStudio, an AI-powered video content creation platform, led by General Manager David Abrams, as previously announced by the Company.

“Our proposed name change to Parabolic represents more than a new brand. This change reflects where we believe the future of software is headed, and the path to strategic growth through investment in high potential businesses. Our continued aim is to build a business that delivers profitable growth both organically and strategically,” said Joe Davy, Founder and CEO of Banzai. “We look forward to sharing more with our shareholders as we move toward a vote on this proposal.”

In connection with the proposed name change, the Company intends to file a proxy statement with the U.S. Securities and Exchange Commission (the “SEC”) shortly and will call a special meeting of shareholders to vote on the proposal. The Company’s Class A common stock and warrants, which currently trade on the Nasdaq Capital Market under the ticker symbols “BNZI” and “BNZIW,” respectively, are expected to begin trading under new ticker symbols “PARA” and “PARAW,” respectively, on August 7, 2026.

About
Parabolic

Parabolic builds agentic applications that power the future of business. Parabolic has over 150,000 customers including Amazon, Dell, Salesforce, Aflac, Thermo Fisher Scientific, RBC Wealth Management, and Fitch Group. Learn more at www.parabolic.io. For investors, please visit ir.banzai.io.

Important Additional Information and Where to Find It

In connection with the proposed name change, the Company intends to file a proxy statement with the SEC. This press release is not a substitute for the proxy statement that the Company will file with the SEC or any other document that the Company may file with the SEC in connection with the proposed name change. Before making any voting decision, the company’s shareholders are urged to read the proxy statement and all other relevant documents filed or to be filed with the SEC in connection with the proposed name change, as well as any amendments or supplements to those documents, carefully and in their entirety when they become available because they will contain important information about the proposed name change. Shareholders will be able to obtain a free copy of the proxy statement, as well as other filings containing information about the Company, without charge, at the SEC’s website (http://www.sec.gov) once such documents are filed with the SEC, or by directing a request to the Company’s investor relations department.

Participants in the Solicitation

The Company and its directors and executive officers may be deemed to be participants in the solicitation of proxies from the Company’s shareholders in connection with the proposed name change. Information regarding the Company’s directors and executive officers, including a description of their direct or indirect interests in the proposed name change, by security holdings or otherwise, will be set forth in the proxy statement when it is filed with the SEC. Free copies of these documents may be obtained as described in the preceding paragraph.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements often use words such as “believe,” “may,” “will,” “estimate,” “target,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “propose,” “plan,” “project,” “forecast,” “predict,” “potential,” “seek,” “future,” “outlook,” and similar variations and expressions. Forward-looking statements are those that do not relate strictly to historical or current facts. Examples of forward-looking statements may include, among others, statements regarding the proposed name change to Parabolic Technologies, Inc. and the anticipated timing and effects thereof; the realignment of Banzai’s operations into the ConnectAndSell, Banzai and CreateStudio business units and the anticipated benefits thereof; Banzai’s ability to successfully operate its business and provide value to stockholders; Banzai’s future financial, business and operating performance and goals; ongoing, future or ability to maintain or improve its financial position, cash flows, and liquidity and its expected financial needs; potential financing and ability to obtain financing; strategy and strategic goals, including being able to capitalize on opportunities; expectations relating to Banzai’s industry, outlook and market trends; and plans, strategies and expectations for increasing revenue, reducing costs and executing growth initiatives. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Forward-looking statements are not guarantees of future performance, and our actual results of operations, financial condition and liquidity and development of the industries in which Banzai operates may differ materially from those made in or suggested by the forward-looking statements. Therefore, investors should not rely on any of these forward-looking statements. Factors that may cause actual results to differ materially include changes in the markets in which Banzai operates, the financial markets, economic, business and regulatory factors, the risk that shareholders may not approve the proposed name change, and other factors, such as Banzai’s ability to execute on its strategies. More detailed information about risk factors can be found in Banzai’s Annual Report on Form 10-K and other reports filed by Banzai with the Securities and Exchange Commission. Banzai does not undertake any duty to update forward-looking statements after the date of this press release.

Investor
Relations

Dean Ditto
Chief Financial Officer, Banzai
206 414-1777
ir.banzai.io

Media

Paul Witkowski
Senior Director Financial Reporting, Banzai
[email protected]

SAN ANTONIO, Aug. 06, 2026 (GLOBE NEWSWIRE) — Rackspace Technology® (NASDAQ: RXT), a global enterprise AI infrastructure and solutions provider, today announced the appointment of Pranav Nambiar as Senior Vice President and General Manager, AI Infrastructure. Nambiar will lead the infrastructure, operating model, partnerships and go-to-market strategy behind Rackspace’s AI infrastructure offerings, further strengthening the company’s position as a governed, model-agnostic operator of AI in production for regulated and mission-critical enterprises.

As enterprises move AI out of pilots and into production, demand has shifted from raw GPU capacity to governed compute: sovereign environments, compliance by design and operational discipline at scale. Nambiar’s appointment accelerates Rackspace’s investment in exactly that layer.

Nambiar brings more than two decades of experience architecting multi-billion-dollar technology ecosystems and delivering transformative growth at Amazon Web Services, DigitalOcean, Google and Microsoft. At DigitalOcean, he served as Senior Vice President and General Manager of AI and Data Cloud, leading the company’s strategic shift into a premier “AI Neo Cloud” and expanding production inference infrastructure for thousands of customers.

“Enterprise AI has moved past the question of which model to use. The hard problem now is the infrastructure and operating discipline around the model: governed, sovereign, compliant and running in production at scale,” said Gajen Kandiah, CEO of Rackspace Technology. “Pranav has spent his career building and scaling AI and cloud platforms at hyperscale, and he knows what it takes to run AI as a reliable operation rather than a pilot. His leadership will accelerate the infrastructure, operating model and partnerships behind sovereign, compliant and enterprise-ready AI for our customers. I am delighted to welcome him to Rackspace.”

Prior to his tenure at DigitalOcean, Nambiar led Google’s generative AI and data services portfolio. At AWS, he led services including Amazon DynamoDB, Amazon Elasticsearch and Amazon SageMaker, and played a key role in shaping the company’s data and AI platforms. Earlier in his career, Nambiar held multiple leadership positions at Microsoft, where he led digital strategies across its mobile, search and Windows businesses. He has advised C-suite executives and board members on enterprise AI, agentic innovation and autonomous systems for regulated industries.

“Rackspace has something rare in this market: real infrastructure, deep operational experience and the trust of enterprises in the most demanding regulated sectors,” said Nambiar. “The next phase of enterprise AI will be won in production, and I look forward to building the platform that gets customers there.”

About Rackspace Technology

Rackspace Technology® (NASDAQ: RXT) is the operator of the full enterprise AI stack from governed private cloud to AI inference and agents in production. With an Outcomes-as-a-Service model built on secure infrastructure, data foundations and forward-deployed engineering, Rackspace delivers business results for regulated and mission-critical industries where governance, sovereignty and uptime are non-negotiable. Learn more at www.rackspace.com.

Media Contact:
Will Link
[email protected]